Bortezomib Is Highly Effective For Pure Red Cell Aplasia After ABO-Incompatible Hematopoietic Stem Cell Transplantation

被引：0
|
作者：
Khan, Fatima
Linden, Michael A.
Zantek, Nicole D.
Vercellotti, Gregory M.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.5495.5495
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5495
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation
    Khan, F.
    Linden, M. A.
    Zantek, N. D.
    Vercellotti, G. M.
    TRANSFUSION MEDICINE, 2014, 24 (03) : 187 - 188
  • [2] Bortezomib: Successful treatment of refractory pure red cell aplasia after ABO-incompatible stem cell transplantation
    Lukic, Stefan
    Menzel, Helge
    Benk, Janka
    Sitskaya, Xenia
    Drewniock, Petra
    Basara, Nadezda
    BONE MARROW TRANSPLANTATION, 2019, 54 : 279 - 280
  • [3] Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation
    Zhu, Panpan
    Wu, Yibo
    Cui, Dawei
    Shi, Jimin
    Yu, Jian
    Zhao, Yanmin
    Lai, Xiaoyu
    Liu, Lizhen
    Xie, Jue
    Huang, He
    Luo, Yi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation
    Fang, Baijun
    Song, Yongping
    Li, Ning
    Li, Jing
    Han, Qin
    Zhao, Robert Chunhua
    ANNALS OF HEMATOLOGY, 2009, 88 (03) : 261 - 266
  • [5] Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation
    Baijun Fang
    Yongping Song
    Ning Li
    Jing Li
    Qin Han
    Robert Chunhua Zhao
    Annals of Hematology, 2009, 88 : 261 - 266
  • [6] Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation
    Gao, Yang
    Gao, Fei
    Shi, Jimin
    Fu, Huarui
    Huang, He
    Zhao, Yanmin
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2021, 22 (08): : 695 - 700
  • [7] Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation
    Bolan, CD
    Leitman, SF
    Griffith, LM
    Wesley, RA
    Procter, JL
    Stroncek, DF
    Barrett, AJ
    Childs, RW
    BLOOD, 2001, 98 (06) : 1687 - 1694
  • [8] Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study
    Longval, Thomas
    Galimard, Jacques-Emmanuel
    Lepretre, Anne-Claire
    Suarez, Felipe
    Amiranoff, Denise
    Cazaux, Marine
    Kaphan, Eleonore
    Michonneau, David
    Dhedin, Nathalie
    Coman, Tereza
    Quoc, Stephanie Nguyen
    de Latour, Regis Peffault
    Resche-Rigon, Matthieu
    de Fontbrune, Flore Sicre
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 814 - 826
  • [9] Rituximab for pure red cell aplasia after ABO incompatible allogeneic stem cell transplantation
    De Matteis, S
    Sorà, F
    Laurenti, L
    Chiusolo, P
    Zini, G
    Piccirillo, N
    Farina, G
    Tamani, M
    Leone, G
    Sica, S
    BONE MARROW TRANSPLANTATION, 2004, 33 : S341 - S341
  • [10] Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation
    Zhu, Kang-Er
    Li, Jun-Ping
    Zhang, Tao
    Zhong, Juan
    Chen, Jie
    HEMATOLOGY, 2007, 12 (02) : 117 - 121
12345